Home/ Stocks/ ACIU

AC Immune SA

ACIU XNAS

$2.23 +0.08 (+3.79%) ▲ 15-min delayed

Open

$2.10

High

$2.25

Low

$2.10

Volume

180.4K

Market Cap

$221.72M

About AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Employees: 122 Website →

Related Market News

No specific coverage for ACIU yet. Check out our latest market news or earnings calendar.

Get ACIU Alerts

Stay ahead with breaking news, price alerts, and expert analysis on AC Immune SA.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.